Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Automatic Data Processing Unlikely to See Valuation Lift Despite AWS Deal, UBS Says

Automatic Data Processing Unlikely to See Valuation Lift Despite AWS Deal, UBS Says

MT newswireMT newswire2026/09/09 16:54
12:54 PM EDT, 09/09/2026 (MT Newswires) -- Automatic Data Processing (ADP) is unlikely to see a meaningful valuation boost from its expanded cloud partnership with Amazon.com's (AMZN) Amazon Web Services, as macro and industry concerns continue to weigh on the human-resources software sector, UBS Securities said Tuesday in a report. ADP and AWS broadened their collaboration to move more of ADP's core payroll and tax systems onto AWS, including upgrades to its AI-driven tools and data platform. UBS said the initiative is strategically useful, though not enough to shift investor sentiment. Labor-market indicators point to low churn, with muted hiring and separations, UBS said. The firm continues to prefer Paycom Software (PAYC) on product-driven share gains and stronger capital return. UBS rates ADP stock neutral with a $290 price target. ADP shares fell 0.9% in Wednesday trading, Amazon dropped 2.1%, and Paycom declined 1.1%. Price: 265.66, Change: -2.31, Percent Change: -0.86
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading

CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

智通财经•2026/11/05 01:51
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response

According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.

智通财经•2026/11/05 01:36

Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test

Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).

智通财经•2026/11/05 01:07
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test